The number of patients in each cohort is very low I believe only 4 per cohort and many are not FR positive. It is possible once they start the phase 1b portion of the 1456 trial they may pick up speed but that would require recruitment of many more sites. Ron Ellis has mentioned in prior biotech meetings he expected to quickly recruit for the phase 1b trial and I hope he follows through. With all the new oncology platforms in development, especially in immunotherapy, the SOC is in flux for many of the indications they hope to find success. Time is of the essence
I have been disappointed in the slow movement forward on the phase 1 trials using the tubulysin drug with about 20 patients enrolled in over a 6 month time frame. Now seeing the further development of ECYT technology may explain this as they have more potent/effective drugs now in development using antifolate ligands and perhaps multiple drug payloads.
as per their recent press release for AACR
High affinity antifolates can be used in an SMDC format serving as both a high affinity targeting ligand and as a second drug having different, and perhaps a complementary mechanism of action to yield greater antitumor activity.